Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group.

N Engl J Med. 2004 Oct 7;351(15):1521-31.

2.

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF.

N Engl J Med. 1998 Jul 9;339(2):61-8.

3.

Lamivudine as initial treatment for chronic hepatitis B in the United States.

Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA.

N Engl J Med. 1999 Oct 21;341(17):1256-63.

4.

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL.

Antivir Ther. 2007;12(8):1295-303.

PMID:
18240869
5.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group.

N Engl J Med. 2006 Mar 9;354(10):1011-20. Erratum in: N Engl J Med. 2006 Apr 27;354(17):1863.

6.

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.

N Engl J Med. 2005 Jun 30;352(26):2682-95.

7.

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group.

N Engl J Med. 2006 Mar 9;354(10):1001-10.

8.

Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.

Hui CK, Leung N, Shek WH, Zhang HY, Luk JM, Poon RT, Lo CM, Fan ST, Lau GK; Hong Kong Liver Fibrosis Study Group.

J Clin Gastroenterol. 2008 May-Jun;42(5):533-8. doi: 10.1097/MCG.0b013e31804bbdff.

PMID:
18344885
9.
10.

A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.

Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD.

Hepatobiliary Pancreat Dis Int. 2004 May;3(2):188-93.

11.

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.

van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Liver Int. 2006 May;26(4):399-405.

PMID:
16629642
12.

Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.

Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P.

Antivir Ther. 2005;10(6):709-13.

PMID:
16218169
13.

[Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].

Wang L, Yan J, Zhang ZH, Wang JB, Du YZ, Li XY, Wang YZ.

Zhonghua Gan Zang Bing Za Zhi. 2004 Oct;12(10):585-8. Chinese.

PMID:
15504286
14.

Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.

Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H.

J Gastroenterol Hepatol. 2007 Nov;22(11):1929-35.

PMID:
17914972
15.

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.

Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study Group.

Gut. 2011 Aug;60(8):1109-16. doi: 10.1136/gut.2010.221846. Epub 2011 Jan 26.

PMID:
21270118
16.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

N Engl J Med. 2004 Sep 16;351(12):1206-17.

17.

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M.

Gastroenterology. 2003 Dec;125(6):1714-22.

PMID:
14724824
18.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
19.

Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.

Haché C, Villeneuve JP.

Expert Opin Pharmacother. 2006 Sep;7(13):1835-43. Review.

PMID:
16925509
20.

A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.

Sharma YR, Miah AR, Saha SK, Mohammed S, Rahman M, Roy PK, Hasan M.

Nepal Med Coll J. 2004 Dec;6(2):106-11.

PMID:
16295739
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk